Immune Checkpoint Inhibition: Unfettered T Cells Can Control and Eliminate Tumors - CME-Certified
Society for Immunotherapy of Cancer (SITC) and Medscape Oncology are excited to announce our third activity, "Immune Checkpoint Inhibition: Unfettered T Cells Can Control and Eliminate Tumors." The goal of this activity is to focus on how the immune system can be used to target cancer and how to distinguish immune therapy responses from responses to the agents routinely used in clinical practice.
This activity is part of Clinical Advances in Immuno-Oncology, a new, robust online learning center designed to provide oncologists with FREE, CME-certified education on the topic of immunotherapy. This online learning center was developed through a strategic partnership between SITC and Medscape, and it includes a variety of CME-certified educational activities.
During this engaging program, participants will be prompted to answer questions related to the three-panelist discussion, and physicians can earn a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Throughout 2014, SITC and Medscape will release additional unique CME-certified activities covering topics ranging from immunology fundamentals to tumor-specific immunotherapy education. Please stay tuned for additional activities to come!
Previously Released Activities
 |
Tumor Immunity: Exploring the Role of a Checkpoint CME |
 |
Concepts in Immuno-Oncology: Understanding the Key Players CME |
